Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand.
NET
SB-NET
SI-NET
general surgery
neuroendocrine
surgical oncology
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
30
05
2022
received:
02
03
2022
accepted:
31
05
2022
pubmed:
29
6
2022
medline:
13
8
2022
entrez:
28
6
2022
Statut:
ppublish
Résumé
Small intestinal Neuroendocrine Neoplasms (SI-NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI-NEN in Auckland, Aotearoa New Zealand (AoNZ). A retrospective study of all patients diagnosed with a jejunal or ileal SI-NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data. One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10-year disease-specific survival for all patients was 66.1% (95% CI 56.5-75.7%) and 61.8% (95% CI 51.8-71.8%), respectively. Ten-year disease-specific survival was 100% for stage I and II, 74% (95%CI 61.7-84.4%) for stage III and 33.9% (95%CI 16.9-35.6%) for stage IV SI-NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92-5.5) nor distant resection (HR 1.72, 95% CI 0.63-4.7) were significantly associated with a disease-specific or overall survival benefit. This study demonstrates that stage at SI-NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection.
Sections du résumé
BACKGROUND
Small intestinal Neuroendocrine Neoplasms (SI-NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI-NEN in Auckland, Aotearoa New Zealand (AoNZ).
METHODS
A retrospective study of all patients diagnosed with a jejunal or ileal SI-NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data.
RESULTS
One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10-year disease-specific survival for all patients was 66.1% (95% CI 56.5-75.7%) and 61.8% (95% CI 51.8-71.8%), respectively. Ten-year disease-specific survival was 100% for stage I and II, 74% (95%CI 61.7-84.4%) for stage III and 33.9% (95%CI 16.9-35.6%) for stage IV SI-NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92-5.5) nor distant resection (HR 1.72, 95% CI 0.63-4.7) were significantly associated with a disease-specific or overall survival benefit.
CONCLUSION
This study demonstrates that stage at SI-NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection.
Identifiants
pubmed: 35762209
doi: 10.1111/ans.17851
pmc: PMC9541869
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1748-1753Subventions
Organisme : Translational Medicine Trust, University of Auckland
Informations de copyright
© 2022 The Authors. ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.
Références
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Cancer. 2011 Aug 1;117(15):3332-41
pubmed: 21246527
Neuroendocrinology. 2016;103(2):125-38
pubmed: 26758972
Asia Pac J Clin Oncol. 2021 Aug;17(4):350-358
pubmed: 33567164
Semin Oncol. 2013 Feb;40(1):100-8
pubmed: 23391117
Br J Surg. 2012 Nov;99(11):1480-6
pubmed: 22972490
J Gastrointest Surg. 2019 May;23(5):1044-1054
pubmed: 30671800
Int J Cancer. 2018 Mar 15;142(6):1139-1147
pubmed: 29082524
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
pubmed: 21349409
Ann Pathol. 2011 Nov;31(5 Suppl):S27-31
pubmed: 22054452
Eur J Surg Oncol. 2017 Oct;43(10):1808-1815
pubmed: 28583792
ISRN Oncol. 2013;2013:420795
pubmed: 23533809
J Am Coll Surg. 2014 Apr;218(4):837-44
pubmed: 24655881
J Oncol Pract. 2018 Aug;14(8):471-482
pubmed: 30096273
JAMA Oncol. 2018 Feb 01;4(2):183-189
pubmed: 29049611
Pancreas. 2017 Jul;46(6):715-731
pubmed: 28609357
Cancer Causes Control. 2010 Jun;21(6):931-8
pubmed: 20419344
Cancer Epidemiol. 2019 Dec;63:101598
pubmed: 31539715
World J Surg. 2010 Jul;34(7):1500-5
pubmed: 20237925
Cancer. 2015 Feb 15;121(4):589-97
pubmed: 25312765
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Ann Oncol. 2001 Sep;12(9):1295-300
pubmed: 11697843